|
|
||||||||


*
QLT PhotoTherapeutics Inc., Vancouver, BC, Canada;
Department of Microbiology and Immunology, Faculty of Science, University of British Columbia, Vancouver, BC, Canada; and
Department of Pathology and Laboratory Medicine, St. Pauls Hospital-University of British Columbia, Vancouver, BC, Canada
We have explored the effect of photodynamic therapy (PDT) with verteporfin on the induction and expression of contact hypersensitivity (CHS) to 2,4-dinitrofluorobenzene (DNFB) in normal mice and IL-10-deficient mice. Our results indicate that DNFB sensitized mice given PDT with verteporfin and whole body red light irradiation exhibited a significant reduction in CHS compared with control animals. Administration of rIL-12 reversed the effect(s) of PDT as did treatment of mice with anti-IL-10-neutralizing Ab. Knockout mice deficient in IL-10 were found to be resistant to the inhibitory effects of PDT. In vitro proliferative responses using spleen cells from DNFB-sensitized and PDT-treated mice showed a significantly lower response to DNBS as compared with cells from DNFB-sensitized mice or DNFB and PDT-treated IL-10-deficient mice. Finally, naive mice exposed to PDT exhibited an increase in skin IL-10 levels, which peaked between 72 and 120 h post-PDT. Together these data support the role of IL-10 as a key modulator in the inhibition of the CHS response by whole body PDT.
This article has been cited by other articles:
![]() |
Y. Kawakami, N. Inagaki, S. Salek-Ardakani, J. Kitaura, H. Tanaka, K. Nagao, Y. Kawakami, W. Xiao, H. Nagai, M. Croft, et al. Regulation of dendritic cell maturation and function by Bruton's tyrosine kinase via IL-10 and Stat3 PNAS, January 3, 2006; 103(1): 153 - 158. [Abstract] [Full Text] [PDF] |
||||
![]() |
A Hogan, U Behan, and D J Kilmartin Outcomes after combination photodynamic therapy and immunosuppression for inflammatory subfoveal choroidal neovascularisation Br J Ophthalmol, September 1, 2005; 89(9): 1109 - 1111. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |